Improvements in Implantable Glucose Sensors
1 R43 DK48611-01A1,
The NIH sponsored Diabetes Control and Complications Trial (DCCT study) clearly demonstrates that lglucose control dramatically slows down the onset of the devastating complications of diabetes. Howeglucose control is both difficult and potentially hazardous. Hypoglycemia occurs 2-3 times more ofteinsulin management. Half of these episodes occur during sleep. A third of daytime episodes occur wita means of tracking glucose continuously with trend displays and alarm functions is needed to reducefacilitating tighter control of blood glucose. Phase l will take a subcutaneously implantable glucosbeen tested through three months in a dog model, and improving reliability for eventual human trialsstabilize capillary blood supply at the inside of the sensors foreign body capsule by using a promison material microarchitecture stimulation of chronic granuloma tissue. In additional efforts to imprwill quantify in vivo membrane enzyme decay rates and use this information for better sensor lifetimsubsequent improvements in membrane formulation. Upon completion of this Phase l research, an applicto the Human Subjects Committee of the University of Wisconsin Medical School seeking permission forclinical trials of this sensor during Phase II of this proposal.
Small Business Information at Submission:
Principal Investigator:Mark Shults
Markwell Medical Institute,
1433 Valley View Drive Racine, WI 53405
Number of Employees: